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Abbreviations used: 
LM: lentigo maligna 
LMM:  lentigo maligna melanoma 
CD:  cluster of differentiation 
od: once daily 
CI: confidential interval 
y: year(s) 
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Abstract. 
Background: More data are needed to define factors that predict long-term success after 
imiquimod therapy for lentigo maligna (LM). 
Objective: To determine the demographic, clinical, and histological prognostic markers of 
relapse-free survival in LM patients treated with imiquimod. 
Methods: Single-arm, open-label, non-randomized, prospective study. 
Results: Eighty-nine patients with histologically confirmed LM and a median follow-up time of 
4.8 years after imiquimod treatment were included in our study. Sixteen patients (18%) 
relapsed. Statistically significant indicators  of an increased risk of local recurrence included: 
the total number of melanocytes, the number of basal and suprabasal melanocytes and the 
number of pagetoid spreading melanocytes.  
Limitations: Our study was a single-center, non-randomized study. 
Conclusion: An assessment of different melanocyte fractions in the diagnostic baseline 
biopsy may help to predict the response of lentigo maligna to imiquimod therapy.
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Capsule summary: 
Different therapeutic modalities (surgery, radiotherapy, imiquimod) have been used in the 
treatment of lentigo maligna. 
Imiquimod is associated with a recurrence rate of about 18%, with a higher recurrence rate 
being associated with an increased number of melanocytes. 
Imiquimod may be an acceptable nonsurgical option after assessing melanocyte fractions in 
the diagnostic baseline biopsy.
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Introduction 
Lentigo maligna (LM), a melanoma in situ on chronically sun-damaged skin, mainly affects 
elderly patients and has a strong predilection for the head and neck region (1, 2).  Several 
therapeutic modalities, such as surgery, cryotherapy (3, 4) and radiotherapy (5-7), are used. 
Surgical excision with safety margins (usually 5 millimeters) is the treatment of choice.  
Imiquimod is a topical immune response modifier that has been recently suggested to be a 
valuable alternative treatment to surgery in LM, especially in cases with larger lesions 
located on the face in elderly and comorbid patients (1, 8-16), when surgery is not indicated 
or cannot be performed. It has also been proposed as a neo- or post-adjuvant treatment 
option to operative procedures (9, 12-14). Recurrence of LM or LMM after treatment with 
imiquimod has also been observed in some patients (17).  
The aim of our study was to evaluate the response of LM to nonsurgical treatment with 5% 
imiquimod cream in a cohort of patients with long-term follow-up. Furthermore, the role of 
demographic, clinical and histological features for the long-term efficacy of imiquimod 
treatment in LM patients was assessed.  
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Methods. 
Patients, treatments and assessments: Between 2003 and 2013, 89 patients (55 women 
and 34 men) with histologically confirmed LM were enrolled in the study. The patients were 
instructed to apply 5% imiquimod cream (Aldara®, 3M Pharma, Rueschlikon, Switzerland), 
with or without occlusion, to cover the macroscopically pigmented area, as described 
elsewhere (16), once or twice daily, until a weeping erosion developed. All patients 
underwent regular clinical follow-ups at the Department of Dermatology of the University 
Hospital of Bern, Switzerland.  
The following patient data were analyzed: age at the beginning of the therapy, sex and 
Fitzpatrick skin phototype, side effects and clinical response during therapy, size and location 
of the lesion, occurrence of relapse, time from the beginning of the therapy to relapse, date 
of the last clinical follow-up, death and other skin malignancies. 
 
Histological evaluation: Punch biopsies and excisional biopsies were fixed in formalin and 
embedded in paraffin using routine techniques. The diagnoses of LM was made by at least 
two board certified dermatopathologists by analyzing hematoxylin-eosin stained slides, as 
well as immunohistochemical stainings for melan-A antigen. The total number of 
melanocytes, the number of basal and suprabasal melanocytes, and the number of pagetoid 
spreading melanocytes (i.e., melanocytes above the basal and suprabasal layers of the 
epidermis) were assessed on melan-A stained tissue sections using a conventional light 
microscopy with an integrated millimetric scale.  All of the parameters are indicated as 
cells/positive events per mm epidermis. As the epidermis in these mainly elderly individuals 
with sun damaged skin was always very thin, counting cells linearly along the length of the 
epidermis and indicating cells/events per mm epidermis was more reliable than counting 
cells/events per square mm. Furthermore, the maximal epidermal depth of the melanocytes, 
i.e., usually the maximal depth of the melanocytes along the hair follicle, was estimated. 
Similar to tumor thickness (according to Breslow), the distance between the stratum 
granulosum and the deepest melanocyte was measured. The maximal extent of non-invasive 
melanocytes was called epidermal tumor thickness. 
Study design: This investigator-initiated, open-label, non-randomized, prospective study 
was approved by the local Research Ethics Committee of the University of Bern. Informed 
consent was obtained from all of the patients. All clinical investigations were conducted 
according to the principles of the Declaration of Helsinki. 
Statistical analysis: Descriptive statistics were computed for the patients’ demographic and 
clinical characteristics. Time to relapse was calculated from the beginning of therapy to 
relapse. If the patients were lost to follow-up or died before relapse, they were censored at 
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the time of the last visit. All p-values related to the two-sided test with an alpha level of 0.05 
and R 2.13.0 were used for computations (www.r-project.org). The confidence interval (CI) of 
the hazard ratios for the Cox regression and survival function (for time-to-event variables) 
were calculated based on the cumulative hazard and point wise log (survival). Otherwise, the 
methods used to conduct tests (p-values) and CIs are specified separately. The two-sided 
exact Wilcoxon signed rank test was also used, whereas patients who were censored (lost to 
follow-up or death) were not included in this analysis.  
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Results:  
Patient and tumor characteristics are shown in Table 1. Eighty-nine patients (55 females and 
34 males) with a median age of 72.5 y  (range 38.6-93.8 y) were included in the study. Only 
5 of 89 LM were located outside the face (either on the arm, neck or on the shoulders). No 
LM was found on the trunk or lower extremities. The treatment-induced local inflammatory 
reaction was generally well tolerated, but one patient had to discontinue treatment after 63 
days due to a generalized pruritic macular papular rash. Other side effects, including 
hypopigmentation, persistent erythema and telangiectasia at the treatment site, as well as 
malaise, hair-loss, sleeping problems, herpes labialis and swollen eyes in the morning, were 
observed in 16 patients (18%). Moreover, one patient developed persistent vitiligo-like white 
patches outside the treated area (on the dorsal surfaces of his hands).   
Figure 1 shows the recurrence-free survival over time. During the follow-up period, 16 
relapses were registered (18%). The median time to relapse among relapsed patients was 
1.89 years (mean: 2.34 years). The majority of relapsed patients (n=10) underwent later 
surgical treatment. In four cases, imiquimod cream was re-used. Two patients underwent 
radiotherapy.  
The relative risk of relapse (shown in Table 2 and calculated with an univariable Cox 
regression for time to relapse) increased 1.03 times with each additional number of total 
melanocytes per millimeter (i.e., the more total melanocytes per millimeter the higher the risk 
of relapse), and the risk was statistically significant (p-value 0.0001). Similarly, each 
additional number of basal and suprabasal melanocytes per mm epidermis increased the 
relapse risk of 1.06 times (p-value<0.0001), and each additional number of pagetoid 
spreading melanocytes per mm epidermis is accountable for an increase in relapse of 1.05 
times (p-value 0.0122). 
Other variables, including the presence vs. absence of follicle involvement (HR 0.52, p-value 
0.396), maximal diameter of the lesion (mm; HR 0.98, p-value 0.369), absence vs. presence 
of a clinically visible inflammatory reaction at the treatment site (HR 0.66, p-value 0.521), and 
treatment duration (months; HR 0.91, p-value 0.656), were not statistically significant in 
terms of LM relapse.  
Figure 2 shows clinical pictures, dermatoscopic images, and histological images of 
hematoxylin and eosin and melan A stains before and after therapy with imiquimod 
in a non-relapsed and a relapsed patient. 
To determine the accuracy of the bioptical assessment of LM lesions, a preliminary study 
was performed in ten consecutive cases. All four parameters (the number of total 
melanocytes, number of basal and suprabasal melanocytes, number of pagetoid spreading 
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melanocytes per mm epidermis and tumor thickness) were simultaneously evaluated with a 
punch biopsy and in completely excised LM lesions. All four parameters were higher or equal 
in the punch biopsies compared to the excisional specimens, indicating that the biopsies 
were representative and that no underestimation of the extent of the disease was made 
(supplementary Figure).  
The total number of melanocytes, basal and suprabasal melanocytes, number of pagetoid 
spreading melanocytes per mm of epidermis and tumor thickness obtained from baseline 
biopsies were further compared between relapsed and non-relapsed patients (Figure 3). 
Interestingly, all four parameters were increased in the baseline biopsies of the relapsed 
patients, indicating an increased risk of recurrence. Statistical significance was observed only 
for the total melanocytes.  
 
 
Discussion. 
Lentigo maligna is the most common melanoma of the sun-damaged skin of the elderly (in 
our study, the median age was 72.5 y). As also confirmed by our results, it has a certain 
predilection for the facial region (in our study population, 84 out of 89 LM, that is 94.4%) (1, 
18). The rate of progression of LM to invasive melanoma is low (<5% overall), but the exact 
conditions necessary for these transformations have yet to be elucidated (19, 20). Jeffrey et 
al. postulate that the recurrence rate following nonsurgical therapies ranges between 20% 
and 100%. The recurrence rate after radiotherapy ranges from 1% to 19% and is often 
followed by radiodermatitis, tissue destruction, and scarring and may promote the 
development of squamous-cell carcinomas; therefore, it is not the therapy of choice. 
Similarly, cryotherapy with a recurrence rate between 0 and 40% (21) is not the best 
therapeutic option. Surgical excision remains the treatment of choice for LM, with a 
recurrence rate of 3% after Mohs surgery. Nevertheless, complete surgical treatment is 
sometimes difficult to perform, either because of patients’ comorbidities or due to the risk of 
cosmetic disfigurement. Its limits comprise the location and size of the lesion (9, 22-23). A 
good therapeutic alternative in these cases is topical imiquimod, especially when aesthetic 
issues are involved (9). It has been demonstrated to be a very efficient therapy with a 
relatively low recurrence rate (3, 15, 24, 25). According to Naylor et al, imiquimod shows no 
relapse in over 80% of cases (26). Imiquimod is a topical immune response modifier that acts 
through binding toll-like receptors 7 and 8 on dendritic cells, macrophages and neutrophils 
(27). In LM, imiquimod recruits CD68+ macrophages and cells involved in cytotoxic T-cell 
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responses, including CD 8+ T cells (28). It regulates genes involved in different aspects of 
the immune response, apoptosis and oncogenesis (29).  
The principle aim of our study was to assess the risk factors of LM relapse after treatment 
with imiquimod based on an evaluation of the demographic, clinical and histological features 
of patients and LM lesions. As demonstrated, in relapsed patients (18% of the study 
population) the baseline number of the total melanocytes, as well as the basal and 
suprabasal, and pagetoid spreading melanocytes, per mm epidermis compared to those of 
non-relapsed patients, appeared to be significantly increased and might be an indicator of 
the risk of recurrence. To our knowledge, this is the first time that the previously mentioned 
typing and assessment of melanocytes in LM biopsies has been used. This easy-to-perform, 
inexpensive and statistically relevant method has only been validated for LM patients treated 
with imiquimod.  
To date, visible signs of inflammation at the site of treatment and apparent lesion clearance 
have been considered to be predictors of a good response to/efficacy of the imiquimod 
treatment (12, 13). Our results confirm that the visible signs of inflammation are often 
correlated with successful outcomes; however, this relation was not statistically significant 
(95% CI, 0.18-2.37, p-value: 0.521). Also, other well established diagnostic modalities, 
including dermoscopy (30) and in vivo reflectance confocal microscopy (31), have appeared 
to be helpful in relapse estimation, but they appear not to be statistically significant. The 
literature suggests other predictive (histological) markers, such as CAS protein (32) or 
CD133 (33), that could be useful as prognostic factors, but their estimation is surely more 
expensive than typing of melanocytes.  
Moreover, our study demonstrated (histologically and clinically) an almost a 5-year relapse-
free survival in 82% of patients with LM treated with imiquimod only. The large number of 
study participants (n=89) strengthens the validity and significance of this outcome. Our 
results are compatible with the findings of Fleming et al. and Wong et al. who, respectively, 
identified 67% (4 out of 6 patients) and 22% (6 out of 27 patients) of positive responses after 
treatment with imiquimod only (10, 33). The outcomes from studies where imiquimod was 
used in addition to surgical treatment (9, 12, 13), ablative laser (14) or other topical 
treatments (e.g., tazarotene 0.1%) (15) demonstrated variable effects. To date, complete 
surgery remains the best therapeutic option for LM patients (34- 36).  
In conclusion, in cases where surgery is not an option (due to an esthetically challenging 
localization or the patient’s comorbidities), imiquimod provides favorable outcomes with a low 
risk of relapse, is less painful and has a lower mortality rate due to the treatment. Typing and 
the assessment of melanocytes in a skin biopsy is a cheap and simple method that can help 
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predict the risk of relapse already before treatment and further contribute to the best 
therapeutic decision individually adjusted to each patient.
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Table and figure legends: 
Table 1: Lentigo maligna. Patients’ and tumor characteristics. 
Table 2: Lentigo maligna. The univariable cox regression for time to relapse. 
Figure 1: Lentigo maligna. The Kaplan-Meier (KM) curve showing recurrence-free survival 
probability (± 95% confidence interval, CI). 
Figure 2 : Lentigo maligna. Representative examples of two patients with imiquimod 
therapy. The clinical image (A), dermoscopic image (B), and histological image of 
hematoxylin and eosin (C) and melan A stains (D) before (1 and 3) and after (2 and 4) the 
therapy with imiquimod in a non-relapsed (1 and 2, upper panel) and a relapsed (3 and 4, 
lower panel) patient. Increased numbers of melanocytes (arrowheads) are observed 
preferentially in the basal and suprabasal layer in the histological images of the hematoxylin 
and eosin  (panel 1C, 3C,  and 4C)  and melan A stains (panel 1D, 3D,  and 4D). Pagetoid 
spreading melanocytes (arrows) are visible preferentially in the relapsed lesions (panel 3C, 
3D, 4C, and 4D). 
Figure 3: Lentigo maligna. Histological parameters without relapse (open bars) and 
with relapse (closed bars).  The following histological parameters: A) total melanocytes per 
mm epidermis (p=0.0001), B) epidermal tumor thickness (p=0.4749), C) basal- and 
suprabasal melanocytes (p< 0.0001) and D) pagetoid spreading melanocytes (p=0.0122) 
were assessed for each LM. Error bars indicate the standard deviation. 
Supplementary Figure: Lentigo maligna. Validation of the different histological 
parameters. The following histological parameters: A) total melanocytes per mm of 
epidermis (p=0.027), B) epidermal tumor thickness (p=0.073), C) basal- and suprabasal 
melanocytes per mm epidermis (p=0.02), and D) pagetoid spreading melanocytes per mm 
epidermis (p=0.03) were assessed in punch biopsies (open bars) and total surgical excision 
specimens (closed bars) from 10 consecutive patients. Error bars indicate the standard 
deviation.  
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